Literature DB >> 24962555

Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy.

Hideo Shigematsu1, Takayuki Kadoya1, Norio Masumoto1, Kazuo Matsuura1, Akiko Emi1, Keiko Kajitani1, Ai Amioka1, Morihito Okada2.   

Abstract

BACKGROUND: The aim of this study was to evaluate the significance of FDG-PET/CT for predicting the underestimation of invasive breast cancer in cases of DCIS at needle biopsy. PATIENTS AND METHODS: Of 83 consecutive cases with diagnoses of DCIS at primary needle biopsy who underwent curative surgery between 2010 and 2013, the association between the SUVmax on FDG-PET/CT before excision and the underestimation of invasive breast cancer was examined.
RESULTS: There were 29 (34.9%) cases diagnosed to have invasive breast cancer at excision. Receiver operating characteristics curve analysis showed the cutoff value of the SUVmax to predict underestimation of invasive breast cancer was 1.6. The rates of underestimation were 61.5% for patients with a tumor of SUVmax > 1.6 and 11.4% for patients with a tumor of SUVmax ≤ 1.6 (P < .001). A high value of SUVmax was significantly associated with symptomatic presentation (P < .001), palpability (P < .001), mass formation (P = .013), high Breast Imaging Reporting and Data System category (P = .011), and core needle biopsy (P = .007). In multivariate analysis, high SUVmax was only a significant predictive factor of underestimation of invasive breast cancer (hazard ratio, 11.7; 95% confidence interval, 3.70-37.0; P < .001).
CONCLUSION: SUVmax on FDG-PET/CT is useful for predicting the underestimation of invasive breast cancer in cases of DCIS at needle biopsy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; DCIS; Positron emission tomography; SUV(max); Underestimation

Mesh:

Substances:

Year:  2014        PMID: 24962555     DOI: 10.1016/j.clbc.2014.04.006

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

1.  Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy.

Authors:  Ai Amioka; Norio Masumoto; Noriko Gouda; Keiko Kajitani; Hideo Shigematsu; Akiko Emi; Takayuki Kadoya; Morihito Okada
Journal:  Jpn J Clin Oncol       Date:  2016-02-03       Impact factor: 3.019

2.  Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.

Authors:  Hai-Jeon Yoon; Yemi Kim; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2015-06-11       Impact factor: 5.315

3.  Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.

Authors:  Tomoyuki Fujioka; Kazunori Kubota; Akira Toriihara; Youichi Machida; Kaori Okazawa; Tsuyoshi Nakagawa; Yukihisa Saida; Ukihide Tateishi
Journal:  World J Radiol       Date:  2016-08-28

4.  Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?

Authors:  Lucía Graña-López; Michel Herranz; Inés Domínguez-Prado; Sonia Argibay; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Eur Radiol       Date:  2019-08-02       Impact factor: 5.315

5.  18F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation.

Authors:  Takaaki Fujii; Reina Yajima; Hironori Tatsuki; Hiroyuki Kuwano
Journal:  Mol Clin Oncol       Date:  2017-06-29

6.  The usefulness of fluorodeoxyglucose-PET/CT for preoperative evaluation of ductal carcinoma in situ.

Authors:  Sungchul Kim; Seokjae Lee; Sangwon Kim; Seokmo Lee; Hayong Yum
Journal:  Ann Surg Treat Res       Date:  2018-01-30       Impact factor: 1.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.